News & Publications
Stanford Medicine News: Cancer
Chemotherapy use for early stage breast cancer declined from 2013 to 2015, possibly due to a preference for less toxic treatments, according to researchers at Stanford and the University of Michigan.
CD47 is an important inhibitor of cancer-killing immune cells called macrophages. Now Stanford researchers have identified another, similar way to activate macrophages to destroy cancer cells.
Instead of targeting a molecule called CD19 on the surface of the cancer cells, the new therapy targets a molecule called CD22.
Two novel Stanford studies have uncovered attributes of high-quality, low-cost care for cancer and primary care patients.
A quarterly publication for patients and friends of the Stanford Cancer Institute.
A monthly publication with timely information for the cancer researchers, physicians and staff who make up the membership of the Stanford Cancer Institute.
MD Community Newsletter
This quarterly publication is designed to inform our colleagues in the medical community, and especially physicians who are considering treatment options for their patients with cancer, about current clinical trials and research studies available at the NCI-designated Stanford Cancer Institute.
A publication for our community physicians, Stanford Access offers you a look into the programs and faculty of Stanford Health Care. Learn about the latest diagnostics, treatment solutions and innovative procedures happening at Stanford.